Phillip M. Friden
Directeur/Membre du Conseil chez LipimetiX Development LLC
Profil
Phillip M.
Friden is currently the Director & Vice President at LipimetiX Development LLC.
Previously, he held positions as Founding Scientist at Alkermes, Inc., Vice President-Biology at Faraday Pharmaceuticals, Inc. (Washington), Vice President-Research & Development at Transport Pharmaceuticals, Inc., Vice President-Research & Development at eXIthera Pharmaceuticals, Inc., and Vice President-Research & Development at Periodontix, Inc. He earned a doctorate degree from The State University of New York.
Postes actifs de Phillip M. Friden
| Sociétés | Poste | Début |
|---|---|---|
LipimetiX Development LLC
 LipimetiX Development LLC Pharmaceuticals: MajorHealth Technology LipimetiX Development LLC operates as a biopharmaceutical company. It develops drugs for the treatment of refractory hypercholesterolemia and hypertriglyceridemia, acute pancreatitis, coronary artery, and peripheral artery diseases by decreasing arterial cholesterol content and inflammation. The company is headquartered in Natick, MA. | Directeur/Membre du Conseil | - |
Anciens postes connus de Phillip M. Friden
| Sociétés | Poste | Fin |
|---|---|---|
eXIthera Pharmaceuticals, Inc.
 eXIthera Pharmaceuticals, Inc. BiotechnologyHealth Technology eXIthera Pharmaceuticals, Inc. develops and manufactures stroke prevention and antithrombosis drugs. Its drugs are based on the pathophysiological role of Factor XI in the initiation of intravascular thrombi without causing undue bleeding. The firm’s drug candidates are small, orally active, and highly selective Factor XI inhibitors. The company was founded by Neil J. Hayward and Frans L. Stassen in 2012 and is headquartered in Westborough, MA. | Directeur Technique/Scientifique/R&D | - |
Alkermes, Inc.
 Alkermes, Inc. Pharmaceuticals: MajorHealth Technology Alkermes, Inc. develops and manufactures pharmaceutical products. It offers medicines for the treatment of central nervous system (CNS) diseases. The company was founded by Michael A. Wall, Floyd E. Bloom, Frederick W. K. Brown, Paul R. Schimmel and Alexander G. Rich in 1987 and is headquartered in Waltham, MA. | Corporate Officer/Principal | - |
Faraday Pharmaceuticals, Inc. (Washington)
 Faraday Pharmaceuticals, Inc. (Washington) Drugstore ChainsRetail Trade Faraday Pharmaceuticals, Inc. develops small molecule drugs for the treatment of central nervous system disorders and cardiovascular diseases. The company was founded in 2001 and is headquartered in Seattle, WA. | Corporate Officer/Principal | - |
Periodontix, Inc.
 Periodontix, Inc. Miscellaneous Commercial ServicesCommercial Services Part of ACI Global Corp., Periodontix, Inc. is a biopharmaceutical company that specializes in researching and developing next-generation antimicrobial agents for the prevention and treatment of periodontal disease. The company is based in Watertown, MA. Periodontix was acquired by Demegen, Inc. on July 16, 2001 for $8.02 million. | Directeur Technique/Scientifique/R&D | - |
Transport Pharmaceuticals, Inc.
 Transport Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Transport Pharmaceuticals, Inc. engaged in the development of medical products for the treatment of multiple dermatological diseases. It developed iontophoretic technique to effect trans-dermal drug delivery for a number of dermatological conditions. The company was founded by Dennis I. Goldberg in 1999 and was headquartered in Framingham, MA. | Directeur Technique/Scientifique/R&D | - |
Formation de Phillip M. Friden
| The State University of New York | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Transport Pharmaceuticals, Inc.
Transport Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Transport Pharmaceuticals, Inc. engaged in the development of medical products for the treatment of multiple dermatological diseases. It developed iontophoretic technique to effect trans-dermal drug delivery for a number of dermatological conditions. The company was founded by Dennis I. Goldberg in 1999 and was headquartered in Framingham, MA. | Health Technology |
Faraday Pharmaceuticals, Inc. (Washington)
Faraday Pharmaceuticals, Inc. (Washington) Drugstore ChainsRetail Trade Faraday Pharmaceuticals, Inc. develops small molecule drugs for the treatment of central nervous system disorders and cardiovascular diseases. The company was founded in 2001 and is headquartered in Seattle, WA. | Retail Trade |
Periodontix, Inc.
Periodontix, Inc. Miscellaneous Commercial ServicesCommercial Services Part of ACI Global Corp., Periodontix, Inc. is a biopharmaceutical company that specializes in researching and developing next-generation antimicrobial agents for the prevention and treatment of periodontal disease. The company is based in Watertown, MA. Periodontix was acquired by Demegen, Inc. on July 16, 2001 for $8.02 million. | Commercial Services |
Alkermes, Inc.
Alkermes, Inc. Pharmaceuticals: MajorHealth Technology Alkermes, Inc. develops and manufactures pharmaceutical products. It offers medicines for the treatment of central nervous system (CNS) diseases. The company was founded by Michael A. Wall, Floyd E. Bloom, Frederick W. K. Brown, Paul R. Schimmel and Alexander G. Rich in 1987 and is headquartered in Waltham, MA. | Health Technology |
eXIthera Pharmaceuticals, Inc.
eXIthera Pharmaceuticals, Inc. BiotechnologyHealth Technology eXIthera Pharmaceuticals, Inc. develops and manufactures stroke prevention and antithrombosis drugs. Its drugs are based on the pathophysiological role of Factor XI in the initiation of intravascular thrombi without causing undue bleeding. The firm’s drug candidates are small, orally active, and highly selective Factor XI inhibitors. The company was founded by Neil J. Hayward and Frans L. Stassen in 2012 and is headquartered in Westborough, MA. | Health Technology |
LipimetiX Development LLC
LipimetiX Development LLC Pharmaceuticals: MajorHealth Technology LipimetiX Development LLC operates as a biopharmaceutical company. It develops drugs for the treatment of refractory hypercholesterolemia and hypertriglyceridemia, acute pancreatitis, coronary artery, and peripheral artery diseases by decreasing arterial cholesterol content and inflammation. The company is headquartered in Natick, MA. | Health Technology |
